| 治疗前外周血炎性标志物对EGFR突变阳性晚期非小细胞肺癌患者的预后价值研究 |
| |
| 引用本文： | 许静,马希雅,高红军,杨绍兴,秦海峰,王红,梁伟林,刘晓晴.治疗前外周血炎性标志物对EGFR突变阳性晚期非小细胞肺癌患者的预后价值研究[J].中国肿瘤临床,2022,49(8):395-400. |
| |
| 作者姓名： | 许静 马希雅 高红军 杨绍兴 秦海峰 王红 梁伟林 刘晓晴 |
| |
| 作者单位： | 1.解放军医学院（北京市100853） |
| |
| 基金项目： | 本文课题受首都临床特色应用研究项目（编号:Z181100001718074）资助 |
| |
| 摘 要： | 目的 探讨治疗前外周血炎性标志物在表皮生长因子受体（epidermal growth factor receptor，EGFR）阳性晚期非小细胞肺癌（non-small cell lung cancer，NSCLC）患者中的预后作用。 方法 回顾性分析2015年1月至2018年10月中国人民解放军总医院第五医学中心142例EGFR突变阳性晚期NSCLC患者临床资料。通过受试者工作特征曲线（receiver operating characteristic curve，ROC）确定中性粒细胞与淋巴细胞计数比值（neutrophil-to-lymphocyte ratio，NLR）、血小板与淋巴细胞计数比值（platelet-to-lymphocyte ratio，PLR）、系统免疫炎症指数（systemic immune-inflammation index，SII）和淋巴细胞与单核细胞计数比值（lymphocyte-to-monocyte ratio，LMR）的最佳临界值，应用Kaplan-Meier方法进行生存分析。Cox比例风险模型评估各变量的预测价值。 结果 NLR、PLR、SII和LMR的最佳临界值分别为2.60、167.32、687.39和3.13。根据最佳临界值分别将研究对象分为高值组和低值组，高NLR、PLR和SII组的中位无进展生存期（median progression-free survival，mPFS）及中位总生存期（median overall survival，mOS）均显著低于低值组中相应值，高LMR组mPFS及mOS较低LMR组延长。 结论 治疗前升高的NLR、PLR、SII和降低的LMR可能与接受靶向治疗的EGFR突变阳性晚期NSCLC患者的不良预后相关。
|
| 关 键 词： | 非小细胞肺癌 表皮生长因子受体突变 炎性标志物 预后 |
| 收稿时间： | 2022-01-11 |
Prognostic value of pretreatment peripheral blood inflammatory markers in EGFR-mutant advanced non-small cell lung cancer |
| |
| Affiliation: | 1.Medical School of Chinese PLA, Beijing 100853, China2.Department of Oncology, The Fifth Medical Center, Chinese PLA General Hospital, Beijing 100071, China3.Academy of Military Medical Sciences, Academy of Military Sciences, Beijing 100850, China4.Department of General Medicine, Beijing West Medical District, Chinese PLA General Hospital, Beijing 100853, China |
| |
| Abstract: | Objective To investigate the prognostic value of pretreatment peripheral blood inflammatory markers in epidermal growth factor receptor (EGFR)-mutant advanced non-small cell lung cancer (NSCLC). Methods We retrospectively analyzed clinical data of 142 patients with EGFR-mutant advanced NSCLC treated at The Fifth Medical Center, Chinese PLA General Hospital, from January 2015 to October 2018. Receiver operating characteristic (ROC) curve analysis was employed to determine optimal cutoff values of neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII), and lymphocyte-to-monocyte ratio (LMR) for predicting survival. The Kaplan-Meier method was used for survival analysis. A Cox proportional risk model was used to evaluate the predictive value of each variable. Results The optimal cutoff values of NLR, PLR, SII, and LMR were 2.60, 167.32, 687.39, and 3.13, respectively. Patients were assigned into high and low NLR, PLR, SII, and LMR groups according to the optimal cutoff values. The median progression-free survival (mPFS) and overall survival (mOS) of the high NLR, PLR, and SII groups were significantly shorter than those of the low NLR, PLR, and SII groups, respectively. The mPFS and mOS of the high LMR group were longer than those of the low LMR group. Conclusions High NLR, PLR, and SII and low LMR before treatment may be associated with poor prognosis of patients with EGFR-mutant advanced NSCLC who receive targeted therapy. |
| |
| Keywords: | |
|
| 点击此处可从《中国肿瘤临床》浏览原始摘要信息 |
|
点击此处可从《中国肿瘤临床》下载全文 |
|
